r-axSpA patients (n = 30) | Healthy Donors (n = 32) | P | |
---|---|---|---|
Clinical parameters | |||
Women/men, n/n | 5/25 | 10/22 | 0.180 |
Age, y | 46.40 ± 2.45 | 41.06 ± 1.77 | 0.080 |
BASDAI | 4.42 ± 0.45 | … | |
BASFI | 4.73 ± 0.61 | … | |
BASMI | 3.22 ± 0.31 | … | |
mSASSS | 19.16 ± 3.86 | … | |
Disease duration, y | 13.23 ± 2.07 | … | |
Extra-articular manifestations | |||
➣ Uveitis | 0/30 | 0/32 | |
➣ Psoriasis | 0/30 | 0/32 | |
➣ IBD | 0/30 | 0/32 | |
Laboratory parameters | |||
HLA-B27 (%) | 26/30 (86.67%) | … | |
CRP†, nmol/L | 122.57 ± 31.38 | 13.62 ± 3.25 | < 0.001 |
ESR†, mm/h | 19.84 ± 4.09 | 7.48 ± 1.00 | 0.006 |
TNF-α, pg/mL | 10.89 ± 1.82 | 4.02 ± 1.20 | 0.021 |
IL-1β, pg/mL | 2.46 ± 0.22 | 1.57 ± 0.27 | 0.047 |
Treatments | |||
NSAIDs (%) | 28/30 (93.33%) | … | |
Sulfasalazine (%) | 2/30 (6.67%) | … |